Taro Semba
Overview
Explore the profile of Taro Semba including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
517
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Oshima T, Yamamoto S, Kawakami H, Makino T, Kawazoe A, Masuishi T, et al.
BJC Rep
. 2024 Nov;
2(1):66.
PMID: 39516370
Background: Esophageal cancer is one of the most common types of cancer in Japan. Herein, we report the efficacy and safety of E7389-LF plus the immune checkpoint inhibitor, nivolumab, from...
2.
Kawazoe A, Yamamoto N, Sugimoto N, Kawakami H, Oshima T, Yamaguchi K, et al.
Clin Cancer Res
. 2024 Jan;
30(7):1264-1272.
PMID: 38295160
Purpose: E7389-LF is a liposomal formulation of the microtubule dynamics inhibitor eribulin and has shown preliminary efficacy in the treatment of gastric cancer. Study 120, a phase Ib/II open-label study,...
3.
Nishio M, Murakami S, Kawakami H, Okishio K, Tamiya M, Kobayashi H, et al.
Cancer Res Commun
. 2024 Jan;
4(1):226-235.
PMID: 38181055
Purpose: E7389-LF is a liposomal formulation of eribulin that contributes to tumor vascular remodeling. The phase II part of this phase Ib/II study assessed the efficacy/safety of E7389-LF in combination...
4.
Ito K, Yamaguchi M, Semba T, Tabata K, Tamura M, Aoyama M, et al.
Mol Cancer Ther
. 2023 Oct;
23(2):235-247.
PMID: 37816248
E7130 is a novel anticancer agent created from total synthetic study of the natural compound norhalichondrin B. In addition to inhibiting microtubule dynamics, E7130 also ameliorates tumor-promoting aspects of the...
5.
Ida H, Shimizu T, Nishino M, Nakamura Y, Yazaki S, Katsuya Y, et al.
Cancer Res Commun
. 2023 Jul;
3(7):1189-1199.
PMID: 37435605
Purpose: To determine a recommended dose of liposomal eribulin (E7389-LF) in combination with nivolumab in patients with advanced solid tumors, and to evaluate the safety, efficacy, pharmacokinetics, and biomarker impact...
6.
Doi T, Matsubara N, Naito Y, Kuboki Y, Harano K, Ono M, et al.
Cancer
. 2023 Apr;
129(15):2348-2359.
PMID: 37080942
Background: E7130 is a novel anticancer agent created from a total synthetic study of norhalichondrin B. The authors report the E7130 dose-escalation part of a first-in-human study of patients with...
7.
Shitara K, Hirao M, Iwasa S, Oshima T, Komatsu Y, Kawazoe A, et al.
Clin Cancer Res
. 2023 Feb;
29(8):1460-1467.
PMID: 36730323
Purpose: In the dose-expansion part of this open-label, phase I study, we explored the efficacy and safety of E7389-LF (liposomal formulation of eribulin) in Japanese patients with advanced gastric cancer....
8.
Niwa Y, Adachi K, Tabata K, Ishida R, Hotta K, Ishida T, et al.
Mol Cancer Ther
. 2023 Jan;
22(4):499-510.
PMID: 36696578
Eribulin is a microtubule dynamics inhibitor with tumor microenvironment modulation activity such as vascular remodeling activity. Here, we investigated antitumor and immunomodulatory activities of eribulin and its liposomal formulation (eribulin-LF)...
9.
Makihara K, Yamaguchi M, Ito K, Sakaguchi K, Hori Y, Semba T, et al.
J Magn Reson Imaging
. 2022 May;
56(6):1820-1831.
PMID: 35524730
Background: Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) can provide insight into tumor perfusion. However, a method that can quantitatively measure the intra-tumor distribution of tumor voxel clusters with a distinct...
10.
Masuda N, Ono M, Mukohara T, Yasojima H, Shimoi T, Kobayashi K, et al.
Eur J Cancer
. 2022 May;
168:108-118.
PMID: 35500404
Background: A liposomal formulation of eribulin, E7389-LF, may provide improved pharmacokinetics and allow increased access to tumour tissues. This expansion of a phase 1 study assessed the safety and efficacy...